Subdued Q3 for Ranbaxy; investors jittery about Wockhardt
This article was originally published in Scrip
Weighed down by uncertainties following regulatory action concerning good manufacturing practice (GMP) deviations at their Indian sites, Ranbaxy Laboratories and Wockhardt continue to feel the heat on Indian bourses ahead of their quarterly results later this month.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.